Clinical Trial Update: E-Selectin Nasal Spray to Prevent Stroke Recurrence [Phase 2]

View source ↗

Summary

A Phase 2 trial of E-Selectin nasal spray to prevent stroke recurrence has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke
• Transient Ischemic Attack

Drugs mentioned

• E-Selectin Nasal Spray

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Cerebrovascular Accident, Transient Ischemic Attack | Phase 2 | Status: TERMINATED